Arvinas (ARVN) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 01, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	ARVN
Entity Registrant Name	ARVINAS, INC.
Entity Central Index Key	1,655,759
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		32,350,972

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,191,004	$ 30,912,391
Marketable securities	83,602,865	8,258,982
Account receivable		25,000,000
Other receivable	2,178,878	1,040,452
Prepaid expenses and other current assets	3,545,309	316,903
Total current assets	95,518,056	65,528,728
Property, equipment and leasehold improvements, net	3,347,242	1,298,881
Other assets	20,760	20,760
Total assets	98,886,058	66,848,369
Current liabilities:
Accounts payable	1,300,760	596,527
Accrued expenses	4,851,146	3,545,936
Deferred revenue	13,501,056	13,553,136
Current portion of long-term debt	194,669	159,265
Total current liabilities	19,847,631	17,854,864
Deferred revenue	40,713,950	48,545,625
Long term debt, net of current portion	2,000,000	151,122
Preferred unit warrant liability		50,888
Total liabilities	62,561,581	66,602,499
Commitments and Contingencies
Stockholders’/Members’ equity:
Common stock, $0.001 par value; 3,683,639 shares issued and outstanding as of September 30, 2018	3,684
Accumulated deficit	(286,176,753)	(62,417,397)
Additional paid-in capital	7,377,913
Accumulated other comprehensive loss	(47,223)	(9,751)
Total members’/stockholders’ equity	(278,842,379)	(61,234,562)
Total liabilities and members’/stockholders’ equity	98,886,058	66,848,369
Series A Redeemable Convertible Preferred Units
Current liabilities:
Redeemable convertible preferred units/stock		19,768,025
Series B Redeemable Convertible Preferred Units
Current liabilities:
Redeemable convertible preferred units/stock		41,712,407
Series A Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred units/stock	111,132,408
Series B Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred units/stock	122,965,984
Series C Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred units/stock	$ 81,068,464
Common Units
Stockholders’/Members’ equity:
Common and Incentive units		6,167
Incentive Units
Stockholders’/Members’ equity:
Common and Incentive units		$ 1,186,419

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Common units, par value		$ 0
Common units, issued		1,897,544
Common units, outstanding		1,897,544
Incentive units, par value		$ 0
Incentive units, issued		3,066,734
Common stock, par value	$ 0.001
Common stock, shares, issued	3,683,639
Common stock, shares, outstanding	3,683,639
Series A Redeemable Convertible Preferred Units
Redeemable convertible preferred units/stock, par value		$ 0
Redeemable convertible preferred units/stock, issued		22,463,665
Redeemable convertible preferred units/stock, outstanding		22,463,665
Series B Redeemable Convertible Preferred Units
Redeemable convertible preferred units/stock, par value		$ 0
Redeemable convertible preferred units/stock, issued		24,977,489
Redeemable convertible preferred units/stock, outstanding		24,977,489
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred units/stock, par value	$ 0.001
Redeemable convertible preferred units/stock, issued	22,573,781
Redeemable convertible preferred units/stock, outstanding	22,573,781
Series C Redeemable Convertible Preferred Stock
Redeemable convertible preferred units/stock, par value	$ 0.001
Redeemable convertible preferred units/stock, issued	16,467,066
Redeemable convertible preferred units/stock, outstanding	16,467,066
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred units/stock, par value	$ 0.001
Redeemable convertible preferred units/stock, issued	24,977,489
Redeemable convertible preferred units/stock, outstanding	24,977,489

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 3,375,264	$ 1,668,861	$ 10,883,755	$ 5,006,583
Operating expenses:
Research and development	13,149,879	7,222,897	30,631,531	22,102,713
General and administrative	4,284,231	857,310	7,110,723	2,357,119
Total operating expenses	17,434,110	8,080,207	37,742,254	24,459,832
Loss from operations	(14,058,846)	(6,411,346)	(26,858,499)	(19,453,249)
Other income (expenses)
Other income, net	160,100	607	418,494	1,030
Change in fair value of preferred unit warrant	0	1,546	(193,779)	4,338
Interest income	523,338	24,140	1,273,988	165,606
Interest expense	(12,264)	(12,219)	(32,804)	(38,905)
Total other income	671,174	14,074	1,465,899	132,069
Loss before income taxes	(13,387,672)	(6,397,272)	(25,392,600)	(19,321,180)
Benefit from income taxes	0	0	0	0
Net loss	(13,387,672)	(6,397,272)	(25,392,600)	(19,321,180)
Change in fair value of redeemable convertible preferred stock/units	(112,050,609)	0	(198,366,756)	0
Net loss attributable to common shares/units	$ (125,438,281)	$ (6,397,272)	$ (223,759,356)	$ (19,321,180)
Net loss per common share/unit, basic and diluted	$ (62.38)	$ (3.37)	$ (115.62)	$ (10.18)
Weighted average common shares/units outstanding, basic and diluted	2,010,807	1,897,544	1,935,299	1,897,544

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (13,387,672)	$ (6,397,272)	$ (25,392,600)	$ (19,321,180)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	49,391	9,339	(37,472)	18,043
Comprehensive loss	$ (13,338,281)	$ (6,387,933)	$ (25,430,072)	$ (19,303,137)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Units/Shares and Changes in Members'/Stockholders' Equity (unaudited) - USD ($)	Total	Accumulated Deficit	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Series A Redeemable Convertible Preferred Units	Series B Redeemable Convertible Preferred Units	Series C Redeemable Convertible Preferred Units	Common UnitsMember Units	Common Shares	Series A,B and C Convertible Preferred Shares	Incentive UnitsMember Units
Balance at Dec. 31, 2016					$ 15,300,002	$ 41,609,999
Balance, Units/Shares at Dec. 31, 2016					22,463,665	24,977,489
Balance at Dec. 31, 2016	$ (32,878,901)	$ (33,797,760)		$ (28,679)				$ 6,167			$ 941,371
Balance, Units/Shares at Dec. 31, 2016								1,897,544			9,966,886
Incentive unit-based compensation	162,901										$ 162,901
Incentive unit-based compensation, Units/Shares											232,329
Net loss	(19,321,180)	(19,321,180)
Unrealized gain (loss) on available-for-sale securities	18,043			18,043
Balance at Sep. 30, 2017					$ 15,300,002	$ 41,609,999
Balance, Units/Shares at Sep. 30, 2017					22,463,665	24,977,489
Balance at Sep. 30, 2017	(52,019,137)	(53,118,940)		(10,636)				$ 6,167			$ 1,104,272
Balance, Units/Shares at Sep. 30, 2017								1,897,544			10,199,215
Balance at Dec. 31, 2017					$ 19,768,025	$ 41,712,407
Balance, Units/Shares at Dec. 31, 2017					22,463,665	24,977,489
Balance at Dec. 31, 2017	(61,234,562)	(62,417,397)		(9,751)				$ 6,167			$ 1,186,419
Balance, Units/Shares at Dec. 31, 2017								1,897,544			11,927,381
Incentive unit-based compensation	6,189,011										$ 6,189,011
Incentive unit-based compensation, Units/Shares											5,424,605
Exercise of Series A redeemable convertible preferred warrant					$ 319,667
Exercise of Series A redeemable convertible preferred warrant, Units					110,116
Issuance of Series C redeemable convertible preferred units							$ 55,000,001
Issuance of Series C redeemable convertible preferred units, Units							16,467,066
Change in redemption value of redeemable convertible preferred units	(198,366,756)	(198,366,756)			$ 91,044,716	$ 81,253,577	$ 26,068,463
Net loss	(25,392,600)	(25,392,600)
Conversion of redeemable convertible preferred units to redeemable convertible preferred shares					$ (111,132,408)	$ (122,965,984)	$ (81,068,464)			$ 315,166,856
Conversion of redeemable convertible preferred units to redeemable convertible preferred shares, Units/Shares					(22,573,781)	(24,977,489)	(16,467,066)			64,018,336
Conversion of common and incentive units to common and restricted stock			$ 7,377,913					$ (6,167)	$ 3,684		$ (7,375,430)
Conversion of common and incentive units to common and restricted stock, Units/Shares								(1,897,544)	3,683,639		(17,351,986)
Unrealized gain (loss) on available-for-sale securities	(37,472)			(37,472)
Balance at Sep. 30, 2018										$ 315,166,856
Balance, Units/Shares at Sep. 30, 2018										64,018,336
Balance at Sep. 30, 2018	$ (278,842,379)	$ (286,176,753)	$ 7,377,913	$ (47,223)					$ 3,684
Balance, Units at Sep. 30, 2018	3,683,639
Balance, Units/Shares at Sep. 30, 2018									3,683,639

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (25,392,600)	$ (19,321,180)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	13,473	13,473
Change in fair value of preferred unit warrant liability	193,779	(4,338)
Depreciation and amortization	483,052	246,367
Net accretion of bond discounts/premiums	213,190	312,561
Non-cash compensation	6,189,011	162,901
Changes in operating assets and liabilities:
Account receivable	25,000,000	0
Other receivable	(1,138,426)	887,835
Prepaid expenses and other current assets	(2,565,154)	22,940
Accounts payable	704,233	(648,028)
Accrued expenses	319,657	289,802
Deferred revenue	(7,883,755)	(5,006,582)
Net cash used in operating activities	(3,863,540)	(23,044,249)
Cash flows from investing activities:
Purchase of marketable securities	(114,393,545)	0
Maturities of marketable securities	38,799,000	12,033,000
Sales of marketable securities	0	9,077,435
Purchase of property, equipment and leasehold improvements	(2,209,112)	(577,859)
Net cash provided by (used in) investing activities	(77,803,657)	20,532,576
Cash flows from financing activities:
Repayments of long term debt	(129,191)	(119,885)
Proceeds from long term debt	2,000,000	0
Proceeds from sale of redeemable convertible preferred units	55,000,001	0
Proceeds from exercise of redeemable convertible preferred warrant	75,000	0
Net cash provided by (used in) financing activities	56,945,810	(119,885)
Net decrease in cash and cash equivalents	(24,721,387)	(2,631,558)
Cash and cash equivalents, beginning of the period	30,912,391	5,088,548
Cash and cash equivalents, end of the period	6,191,004	2,456,990
Supplemental disclosure of cash flow information:
Purchases of property, equipment and leasehold improvements unpaid at period end	322,301	0
Deferred offering costs included in accrued expenses	663,252	0
Cash paid for interest	19,331	25,433
Change in fair value of redeemable convertible preferred stock/units	$ (198,366,756)	$ 0

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Arvinas, Inc. (Arvinas) has five wholly owned subsidiaries, Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., Arvinas BRD4, Inc. and Arvinas Winchester, Inc. (collectively, the Company). The Company is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies to degrade disease-causing proteins. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. On October 1, 2018, the Company completed an initial public offering (IPO) in which the Company issued and sold 7,500,000 shares The Company’s Board of Managers approved a one-for-3.25 reverse stock split of its issued and outstanding shares of common units and a proportional adjustment to the existing conversion ratios for the Company’s Series A, Series B, and Series C preferred units effective as of September 14, 2018. Accordingly, all share/unit and per share/unit amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse unit split and adjustment of the preferred unit conversion ratios. Immediately prior to the effectiveness of the registration statement on September 26, 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. Pursuant to the plan of conversion, each outstanding Series A, Series B, and Series C preferred units converted into an equal number of shares of Series A, Series B, and Series C preferred stock, each outstanding common unit converted into a share of common stock and each outstanding incentive unit converted into a number of shares of common stock and restricted stock based on a conversion price determined by the board of directors. The Company issued 1,786,095 shares of common stock and 1,268,923 shares of restricted stock. On October 1, 2018, all of the outstanding shares of convertible preferred stock automatically converted into 19,697,928 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. The financial statements as of September 30, 2018, including share and per share amounts, do not give effect to the IPO, as it closed on October 1, 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Financial Statements The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the Securities Exchange Commission on September 27, 2018 (the Prospectus). The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases During the nine months ended September 30, 2018, there were no changes to the Company’s significant accounting policies as described in Note 2 to the financial statements included in the Company’s consolidated financial statements as of December 31, 2017 and 2016 and for the years then ended included in the Prospectus.

Research Collaboration and Lice

Research Collaboration and License Agreements	9 Months Ended
	Sep. 30, 2018
Research Collaboration And License Agreements [Abstract]
Research Collaboration and License Agreements	3. Research Collaboration and License Agreements In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer, Inc. (the Pfizer Agreement) Under the terms of the Pfizer Agreement, the Company received an upfront non-refundable payment and certain additional payments totaling $28.0 million in the nine months ended September 30, 2018 in exchange for use of the Company’s technology license and to fund Pfizer-related research as defined within the agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is also eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. The Company is also entitled to receive up to $225 million in development milestone payments and up to $550 million in sales-based milestone payments for all designated targets under the Pfizer Agreement, as well as tiered royalties based on sales. In September 2015, the Company entered into an Option and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (the Genentech Agreement). During 2015, the Company received an upfront non-refundable payment of $11.0 million in exchange for use of the Company’s technology license and to fund Genentech-related research as defined within the Genentech agreement. In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (the Genentech Modification), amending the Genentech Agreement. Under the Genentech Modification, the Company received additional upfront non-refundable payments of $34.5 million to fund Genentech-related research and Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestones based on sales thresholds as well as tiered royalties based on sales. In April 2015, the Company entered into a Research Collaboration and License Agreement with Merck Sharp & Dohme Corp. (the Merck Agreement). During 2015, the Company received an upfront non-refundable payment of $7 million, which is being recognized as revenue over the total estimated period of performance, in exchange for use of the Company’s technology license. The Merck Agreement also provided for research program funding to support Merck-related research. The Merck Agreement expired in April 2018. Information about contract liabilities is as follows: September 30, December 31, 2018 2017 Contract liabilities $ 54,215,006 $ 62,098,761 Revenues recognized in the period from: Amounts included in deferred revenue in previous periods $ 10,354,342 $ 6,600,000 Changes in deferred revenue from December 31, 2017 to September 30, 2018 were due to billings of $3.0 million under the Pfizer Agreement and $10.9 million of revenue recognized on the research collaboration and license agreements. The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of September 30, 2018 was $54.2 million, which is expected to be recognized as revenue in years ending: December 31 Remainder of 2018 $ 3.4 2019 13.5 2020 13.5 2021 13.5 2022 8.6 2023 1.7 $ 54.2

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments Level 1—Inputs are based upon observable or quoted prices for identical instruments traded in active markets. Level 2—Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company’s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. Level 3—Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The Company’s marketable securities consist of corporate bonds and a government bond which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level 2 inputs. The fair value of the preferred unit warrant liability is measured on a recurring basis and is considered a Level 3 instrument in the fair value hierarchy. See Note 7 for the valuation method used and significant assumptions used in the valuation. The following is a summary of the Company’s available-for-sale securities as of September 30, 2018 and December 31, 2017. September 30, 2018 Gross Gross Description Effective Maturity Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds 2018-2019 $ 82,650,526 — (46,931 ) $ 82,603,595 Government securities 2018 999,562 (292 ) 999,270 $ 83,650,088 — (47,223 ) $ 83,602,865 December 31, 2017 Gross Gross Description Effective Maturity Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds 2018 $ 8,268,732 — $ (9,751 ) $ 8,258,982 The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of: September 30, 2018 Description Level 1 Level 2 Level 3 Total Assets: Corporate bonds $ — $ 82,603,595 $ — $ 82,603,595 Government securities $ — $ 999,270 $ — $ 999,270 December 31, 2017 Description Level 1 Level 2 Level 3 Total Assets: Corporate bonds $ — $ 8,258,982 $ — $ 8,258,982 Liabilities: Preferred unit warrant liability $ — $ — $ 50,888 $ 50,888 The following table presents the changes in Level 3 instruments measured on a recurring basis for the nine months ended September 30, 2018 and 2017: Preferred Unit Warrant Liability September 30, September 30, 2018 2017 Balance at beginning of period $ 50,888 $ 56,759 Change in fair value 193,779 (4,338 ) Exercise of warrant (244,667 ) — Balance at end of period $ — $ 52,421 Fluctuation in the fair value of the Company’s Series A redeemable convertible preferred units is the primary driver for the change in the fair value of the Preferred Unit Warrant liability. As the fair value of the Series A redeemable convertible preferred units increase, the value to the holder of the instrument generally increases. Additionally, unit price volatility is one of the significant unobservable inputs used in the fair value measurement of the Company’s Preferred Unit Warrant liability. Decreases in expected volatility would generally result in a lower fair value measurement.

Property, Equipment and Leaseho

Property, Equipment and Leasehold Improvements	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property, Equipment and Leasehold Improvements	5. Property, Equipment and Leasehold Improvements Property, equipment and leasehold improvements consist of the following at: September 30, 2018 December 31, 2017 Laboratory equipment $ 3,579,854 $ 1,952,685 Office equipment 547,328 305,522 Leasehold improvements 730,643 72,294 4,857,825 2,330,501 Less: accumulated depreciation (1,510,583 ) (1,031,620 ) Property, equipment and leasehold improvements, net $ 3,347,242 $ 1,298,881 Depreciation expense totaled $191,547 and $92,147 for the three months ended September 30, 2018 and 2017, respectively, and $483,052 and $246,367 for the nine months ended September 30, 2018 and 2017, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consisted of the following at: September 30, 2018 December 31, 2017 Employee expenses $ 1,784,061 $ 1,047,022 Research and development expenses 1,912,377 1,982,525 Professional fees and other 1,154,708 516,389 $ 4,851,146 $ 3,545,936

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-Term Debt	7. Long-Term Debt In August 2013, Arvinas, Inc. entered into a Loan Agreement and a Stock Subscription Warrant, with Connecticut Innovations, Inc. (CII). Under the Loan Agreement, the Company can draw up to $750,000 for the purpose of purchasing laboratory equipment, information technology equipment and leasehold improvements. Leasehold improvements are limited to $100,000. Interest on the loan is compounded on a monthly basis at a rate of 7.50% per annum and is required to be paid on a monthly basis beginning on the date of the first draw of funds for 10 months, then with principal payments beginning on June 1, 2015 and payable monthly until the maturity date of July 31, 2019. The Company has the ability to prepay the amount due at any time prior to the maturity date without premium or penalty. The loan is secured by substantially all of the Company’s assets. As of September 30, 2018, and December 31, 2017, the amount outstanding under the Loan Agreement was $214,309 and $343,500, respectively. In connection with the issuance of the loan, and as additional consideration, Arvinas, Inc. granted CII a warrant to purchase 110,116 shares of Arvinas, Inc. Series A Preferred Stock at a purchase price of $0.6811 per share, with a term of 7 years from the date of issuance (CII Series A Preferred Stock Warrant). Effective January 1, 2015, the CII Series A Preferred Stock Warrant was exchanged for a warrant to purchase 110,116 units of the Company’s Series A redeemable convertible preferred units (CII Series A Preferred Unit Warrant). In July 2018, CII exercised the CII Series A Preferred Unit Warrant. The fair value of the CII Series A Preferred Unit Warrant of $61,796 was determined using the Black-Scholes option pricing model and was recorded as a debt discount and is being amortized as non-cash interest expense over the term of the loan. At September 30, 2018 and December 31, 2017, the total unamortized debt discount on the loan totaled $10,299 and $19,569, respectively. Interest expense recorded related to the amortization of the debt discount in each of the nine months ended September 30, 2018 and 2017 was $9,269. The Company evaluated the CII Series A Preferred Unit Warrant issued under authoritative guidance and determined that the CII Series A Preferred Unit Warrant does not meet the conditions to be classified as equity and has classified the CII Series A Preferred Unit Warrant as a liability at fair value on the accompanying condensed consolidated balance sheets. The fair value of the CII Series A Preferred Unit Warrant was determined using the Black-Scholes option pricing model with the following assumptions: December 31, 2017 Expected volatility 100% Expected term (years) 2.67 Risk free interest rate 1.91% Expected dividend yield 0% Fair value of underlying Series A redeemable convertible preferred units $ 0.98 In January 2014, Arvinas, Inc. entered into an Assistance Agreement with the State of Connecticut (2014 Assistance Agreement). Under the terms of the 2014 Assistance Agreement, the Company could borrow from the State of Connecticut in three separate tranches if it meets minimum financing criteria and creates a minimum number of full time jobs in the State of Connecticut. Each of the three tranches were forgivable if the Company maintained a minimum number of full time jobs in the State of Connecticut for a minimum period at the minimum annual salary as defined in the 2014 Assistance Agreement. The 2014 Assistance Agreement requires that the Company be located in the State of Connecticut through January 2024 with a default penalty of repayment of the full original funding amount of $2.5 million plus liquidated damages of 7.5%. Each of the three tranches was forgiven and, in the period forgiven, the amount forgiven was recorded as a component of other income, as it is reasonably assured that the Company will comply with the location requirement. In June 2018, Arvinas, Inc. entered into an Assistance Agreement with the State of Connecticut (2018 Assistance Agreement) to provide funding for the expansion and renovation of laboratory and office space (Project). Under the terms of the 2018 Assistance Agreement, the Company could borrow from the State of Connecticut a maximum of $2.0 million, provided that the funding does not exceed more than 50% of the total Project costs. In September 2018, the Company borrowed $2.0 million under the 2018 Assistance Agreement, bearing interest at 3.25% per annum and interest payments will be required for the first 60 months from the funding date. Thereafter, the loan begins to fully amortize through month 120, maturing in June 2028. According to the terms of the 2018 Assistance Agreement, up to $1.0 million of the funding can be forgiven if the Company meets certain employment conditions, as defined in the agreement. The Company may also be required to prepay a portion of the loan if the employment conditions are not met. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through June 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. Anticipated future minimum payments on long-term debt, excluding the discount on debt of $10,299, for the years ending December 31 are: 2018 $ 29,706 2019 184,603 Beyond 5 years 2,000,000 Total $ 2,214,309 During the three months ended September 30, 2018 and 2017, interest expense was $12,264 and $12,219, respectively. During the nine months ended September 30, 2018 and 2017, interest expense was $32,804 and $38,905, respectively.

Incentive Unit Plans

Incentive Unit Plans	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Incentive Equity Plans	8. Incentive Equity Plans In the Fourth Amendment to the Company’s Incentive Share Plan (the Incentive Plan) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from one to four years. The Incentive Plan was terminated in September 2018. In September 2018, the Company’s board of directors adopted and the Company’s stockholders approved the 2018 Stock Incentive Plan (the 2018 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company’s IPO. The number of common shares initially available for issuance under the 2018 Plan is the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181) issued in respect of incentive units granted under the Incentive Plan that are subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lowest of 4,989,593 shares of the Company’s common stock, 4% of the number of shares of the Company’s common stock outstanding on the first day of the fiscal year and an amount determined by the Company’s board of directors. During the nine months ended September 30, 2018, the Company granted 1,715,368 incentive units to employees and directors under the Incentive Plan. The weighted average fair value of incentive units granted to employees in the nine months ended September 30, 2018 was $4.54 per unit. In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continue to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units, The Company granted 1,257,826 restricted shares to employees and directors as part of the conversion. The Company also granted 1,744,650 stock options to purchase shares of common stock to employees and directors who were holders of incentive units at the time of the incentive unit conversion and 186,150 in new employee grants. The weighted average fair value of stock options granted to employees and directors in the nine months ended September 30, 2018 was $9.87 per share. During the nine months ended September 30, 2018, the Company recognized compensation expense of $5,195,802 relating to the issuance of employee and director incentive units, and at September 30, 2018, there was approximately $18,900,000 of compensation expense that is expected to be amortized over a weighted average period of approximately three years. In September 2018, in connection with the conversion of the incentive units, the Company The fair value of the incentive common units granted during the nine months ended September 30, 2018 and 2017 was determined using the Black-Scholes option pricing model with the following assumptions: September 30, 2018 September 30, 2017 Expected volatility 66-71% 75-78% Expected term (years) 5.6-6.1 1.5-6.1 Risk free interest rate 2.5-2.9% 1.1-2.1% Expected dividend yield 0 % 0 % Fair value of underlying common units $1.08-8.48 $ 0.72 The fair value of the underlying common units indicated above was utilized as the exercise price within the Black-Scholes option pricing model. The fair value of the stock options granted during the nine months ended September 30, 2018 was determined using the Black-Scholes option pricing model with the following assumptions: September 30, 2018 Expected volatility 68 % Expected term (years) 5.0-10.0 Risk free interest rate 2.9-3.0% Expected dividend yield 0 % Exercise price $ 16.00 The following table provides a summary of the incentive unit activity under the Incentive Plan in the nine months ended September 30, 2018. These amounts include incentive units granted to employees, directors and consultants. Units Weighted Average Fair Value Outstanding at December 31, 2017 3,669,963 $ 0.45 Granted 1,715,368 $ 4.54 Forfeited (34,982 ) $ 4.85 Cancelled (5,350,349 ) $ 1.86 Outstanding at September 30, 2018 — $ — The following table provides a summary of the restricted stock grant activity under the Incentive Plan in the nine months ended September 30, 2018. These amounts include restricted stock granted to employees, directors and consultants. Shares Weighted Average Grant Date Fair Value Per Share Unvested restricted stock at December 31, 2017 — $ — Granted 1,268,923 $ 16.00 Unvested restricted stock at September 30, 2018 1,268,923 $ 16.00 The following table provides a summary of the stock option activity under the 2018 Plan in the nine months ended September 30, 2018. These amounts include stock options granted to employees, directors and consultants. Options Weighted Average Fair Value Outstanding at December 31, 2017 — $ — Granted 2,181,810 $ 10.13 Outstanding at September 30, 2018 2,181,810 $ 10.13 Exercisable at September 30, 2018 357,658 $ 9.62 The 1,995,660 stock options to purchase shares of common stock to employees, directors, and consultants granted at the time of the incentive unit conversion have the same vesting terms as the profit units that were outstanding in September 2018 before the profit interests were converted into common stock. At the time of issuance of the stock options, 357,658 stock options to purchase shares of common stock became immediately vested, resulting in stock compensation expense of $3,627,507. At September 30, 2018, there were 1,134,055 restricted shares under the Incentive Plan and 1,949,915 stock options under the 2018 Plan that vested and are expected to vest.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company’s effective tax rate was 0.0% for the nine months ended September 30, 2018 and 2017. The primary reconciling items between the federal statutory rate of 21.0% and 34.0% for the nine months ended September 30, 2018 and 2017, respectively, and the Company’s overall effective tax rate of 0.0% was the effect of the valuation allowance recorded against the full amount of its net deferred tax assets. Valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company is subject to tax in the U.S. Federal jurisdiction and the states of Connecticut and Massachusetts. The Company pays franchise tax in the states mentioned above due to its loss position. As a result, there is no state income tax provision recorded for the nine months ended September 30, 2018 and 2017.

Net Loss Per Common Share_Unit

Net Loss Per Common Share/Unit	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Common Share/Unit	10. Net Loss Per Common Share/Unit Basic and diluted loss per common share/unit were calculated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net loss $ (13,387,672 ) $ (6,397,272 ) $ (25,392,600 ) $ (19,321,180 ) Change in redemption value of preferred shares/units (112,050,609 ) — (198,366,756 ) — Net loss attributable to common shares/units—basic and diluted $ (125,438,281 ) $ (6,397,272 ) $ (223,759,356 ) $ (19,321,180 ) Weighted average number of common shares/units outstanding, basic and diluted 2,010,807 1,897,544 1,935,299 1,897,544 Net loss per common stock/unit $ (62.38 ) $ (3.37 ) $ (115.62 ) $ (10.18 ) The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per common share/unit as the effect would be to reduce the net loss per common share/unit. The incentive units that convert into restricted shares have been excluded from basic loss per share given that the incentive units had no obligation to share in losses and have been excluded from dilutive loss per share due to anti-dilutive effect. The following common share/unit equivalents have been excluded from the calculations of diluted loss per common share/unit because their inclusion would have been antidilutive for the periods ended September 30: 2018 2017 Redeemable convertible preferred stock/units 19,664,047 14,597,268 Incentive units — 3,789,455 Restricted stock 1,268,923 — Stock options 2,181,810 — Preferred unit warrant — 33,881 23,114,780 18,420,604

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Parties	11. Related Parties Dr. Craig Crews, founder of the Company and the Chief Scientific Advisor to the Company, is a common unit holder in the Company and has a consulting agreement with the Company. The Company entered into an amendment to the amended and restated consulting agreement with Professor Crews, which became effective upon the closing of the IPO and continues in effect for three years. Pursuant to the amendment, Professor Crews will be paid $20,833 per month for his services. During nine months ended September 30, 2018 and 2017, the Company paid Professor Crews $113,611 and $112,500, respectively, related to his consulting agreement. In connection with the conversion of incentive units, the Company also granted Professor Crews 235,150 stock options to purchase common stock at an exercise price of $16.00 per share, vesting over three years. During the nine months ended September 30, 2018 and 2017, the Company also paid Yale University, a common unit holder in the Company, $107,289 and $102,063, respectively, for reimbursable patent costs. In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, under the direction of Professor Crews, which was amended in April 2018. The SRA requires quarterly payments of $101,161 through April 2018, in exchange for performing the research on the agreed upon program and related research reports. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement. The total payments made under the SRA for the nine months ended September 30, 2018 and 2017 were $601,161 and $303,482, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the Securities Exchange Commission on September 27, 2018 (the Prospectus). The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases During the nine months ended September 30, 2018, there were no changes to the Company’s significant accounting policies as described in Note 2 to the financial statements included in the Company’s consolidated financial statements as of December 31, 2017 and 2016 and for the years then ended included in the Prospectus.

Research Collaboration and Li_2

Research Collaboration and License Agreements (Tables)	9 Months Ended
	Sep. 30, 2018
Research Collaboration And License Agreements [Abstract]
Summary of Contract Liabilities	Information about contract liabilities is as follows: September 30, December 31, 2018 2017 Contract liabilities $ 54,215,006 $ 62,098,761 Revenues recognized in the period from: Amounts included in deferred revenue in previous periods $ 10,354,342 $ 6,600,000
Transaction Price Allocated to Performance Obligations	The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of September 30, 2018 was $54.2 million, which is expected to be recognized as revenue in years ending: December 31 Remainder of 2018 $ 3.4 2019 13.5 2020 13.5 2021 13.5 2022 8.6 2023 1.7 $ 54.2

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Summary of Company's Available for Sale Securities	The following is a summary of the Company’s available-for-sale securities as of September 30, 2018 and December 31, 2017. September 30, 2018 Gross Gross Description Effective Maturity Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds 2018-2019 $ 82,650,526 — (46,931 ) $ 82,603,595 Government securities 2018 999,562 (292 ) 999,270 $ 83,650,088 — (47,223 ) $ 83,602,865 December 31, 2017 Gross Gross Description Effective Maturity Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds 2018 $ 8,268,732 — $ (9,751 ) $ 8,258,982
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of: September 30, 2018 Description Level 1 Level 2 Level 3 Total Assets: Corporate bonds $ — $ 82,603,595 $ — $ 82,603,595 Government securities $ — $ 999,270 $ — $ 999,270 December 31, 2017 Description Level 1 Level 2 Level 3 Total Assets: Corporate bonds $ — $ 8,258,982 $ — $ 8,258,982 Liabilities: Preferred unit warrant liability $ — $ — $ 50,888 $ 50,888
Summary of Changes In Level 3 Instruments Measured On Recurring Basis	The following table presents the changes in Level 3 instruments measured on a recurring basis for the nine months ended September 30, 2018 and 2017: Preferred Unit Warrant Liability September 30, September 30, 2018 2017 Balance at beginning of period $ 50,888 $ 56,759 Change in fair value 193,779 (4,338 ) Exercise of warrant (244,667 ) — Balance at end of period $ — $ 52,421

Property, Equipment and Lease_2

Property, Equipment and Leasehold Improvements (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Schedule of Property, Equipment and Leasehold Improvements	Property, equipment and leasehold improvements consist of the following at: September 30, 2018 December 31, 2017 Laboratory equipment $ 3,579,854 $ 1,952,685 Office equipment 547,328 305,522 Leasehold improvements 730,643 72,294 4,857,825 2,330,501 Less: accumulated depreciation (1,510,583 ) (1,031,620 ) Property, equipment and leasehold improvements, net $ 3,347,242 $ 1,298,881

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Payables And Accruals [Abstract]
Components of Accrued Expenses	Accrued expenses consisted of the following at: September 30, 2018 December 31, 2017 Employee expenses $ 1,784,061 $ 1,047,022 Research and development expenses 1,912,377 1,982,525 Professional fees and other 1,154,708 516,389 $ 4,851,146 $ 3,545,936

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt	Anticipated future minimum payments on long-term debt, excluding the discount on debt of $10,299, for the years ending December 31 are: 2018 $ 29,706 2019 184,603 Beyond 5 years 2,000,000 Total $ 2,214,309
Series A Preferred Unit Warrant
Schedule of Assumptions Used in Determining Fair Value of Warrant	The fair value of the CII Series A Preferred Unit Warrant was determined using the Black-Scholes option pricing model with the following assumptions: December 31, 2017 Expected volatility 100% Expected term (years) 2.67 Risk free interest rate 1.91% Expected dividend yield 0% Fair value of underlying Series A redeemable convertible preferred units $ 0.98

Incentive Equity Plans (Tables)

Incentive Equity Plans (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Assumptions Used to Determine Fair Value of Incentive Common Units Granted	The fair value of the incentive common units granted during the nine months ended September 30, 2018 and 2017 was determined using the Black-Scholes option pricing model with the following assumptions: September 30, 2018 September 30, 2017 Expected volatility 66-71% 75-78% Expected term (years) 5.6-6.1 1.5-6.1 Risk free interest rate 2.5-2.9% 1.1-2.1% Expected dividend yield 0 % 0 % Fair value of underlying common units $1.08-8.48 $ 0.72 The fair value of the stock options granted during the nine months ended September 30, 2018 was determined using the Black-Scholes option pricing model with the following assumptions: September 30, 2018 Expected volatility 68 % Expected term (years) 5.0-10.0 Risk free interest rate 2.9-3.0% Expected dividend yield 0 % Exercise price $ 16.00
Summary of Incentive Unit Activity	The following table provides a summary of the incentive unit activity under the Incentive Plan in the nine months ended September 30, 2018. These amounts include incentive units granted to employees, directors and consultants. Units Weighted Average Fair Value Outstanding at December 31, 2017 3,669,963 $ 0.45 Granted 1,715,368 $ 4.54 Forfeited (34,982 ) $ 4.85 Cancelled (5,350,349 ) $ 1.86 Outstanding at September 30, 2018 — $ —
Summary of Restricted Stock Grant Activity	The following table provides a summary of the restricted stock grant activity under the Incentive Plan in the nine months ended September 30, 2018. These amounts include restricted stock granted to employees, directors and consultants. Shares Weighted Average Grant Date Fair Value Per Share Unvested restricted stock at December 31, 2017 — $ — Granted 1,268,923 $ 16.00 Unvested restricted stock at September 30, 2018 1,268,923 $ 16.00
Summary of Stock Option Activity	The following table provides a summary of the stock option activity under the 2018 Plan in the nine months ended September 30, 2018. These amounts include stock options granted to employees, directors and consultants. Options Weighted Average Fair Value Outstanding at December 31, 2017 — $ — Granted 2,181,810 $ 10.13 Outstanding at September 30, 2018 2,181,810 $ 10.13 Exercisable at September 30, 2018 357,658 $ 9.62

Net Loss Per Common Share_Unit

Net Loss Per Common Share/Unit (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Basic and Diluted Loss per Common Share/Unit	Basic and diluted loss per common share/unit were calculated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net loss $ (13,387,672 ) $ (6,397,272 ) $ (25,392,600 ) $ (19,321,180 ) Change in redemption value of preferred shares/units (112,050,609 ) — (198,366,756 ) — Net loss attributable to common shares/units—basic and diluted $ (125,438,281 ) $ (6,397,272 ) $ (223,759,356 ) $ (19,321,180 ) Weighted average number of common shares/units outstanding, basic and diluted 2,010,807 1,897,544 1,935,299 1,897,544 Net loss per common stock/unit $ (62.38 ) $ (3.37 ) $ (115.62 ) $ (10.18 )
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	The following common share/unit equivalents have been excluded from the calculations of diluted loss per common share/unit because their inclusion would have been antidilutive for the periods ended September 30: 2018 2017 Redeemable convertible preferred stock/units 19,664,047 14,597,268 Incentive units — 3,789,455 Restricted stock 1,268,923 — Stock options 2,181,810 — Preferred unit warrant — 33,881 23,114,780 18,420,604

Nature of Business - Additional

Nature of Business - Additional Information (Details) $ / shares in Units, $ in Millions	Oct. 01, 2018USD ($)$ / sharesshares	Oct. 31, 2018$ / sharesshares	Sep. 30, 2018USD ($)Subsidiary
Nature Of Business [Line Items]
Number of wholly owned subsidiaries | Subsidiary			5
Other Current Assets
Nature Of Business [Line Items]
Deferred fees and expenses | $			$ 2.8
Subsequent Event
Nature Of Business [Line Items]
Fees and expenses | $	$ 12
Preferred stock outstanding	0
Subsequent Event | Restricted Stock
Nature Of Business [Line Items]
Restricted shares issued	1,268,923
Common Stock
Nature Of Business [Line Items]
Reverse stock split, description			The Company’s Board of Managers approved a one-for-3.25 reverse stock split of its issued and outstanding shares of common units
Common Stock | Subsequent Event
Nature Of Business [Line Items]
Gross proceeds from sale of shares in Initial public offering before fees and expenses | $	$ 123.2
Reverse stock split, conversion ratio	0.3077
Common shares issued	1,786,095
Common stock issued for conversion of convertible preferred stock	19,697,928
Common Stock | Initial Public Offering | Subsequent Event
Nature Of Business [Line Items]
Shares issued and sold	7,500,000
Share price, issued and sold | $ / shares	$ 16
Common Stock | Over-Allotment Option | Subsequent Event
Nature Of Business [Line Items]
Shares issued and sold		200,482
Share price, issued and sold | $ / shares		$ 16

Research Collaboration and Li_3

Research Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	4 Months Ended	9 Months Ended
	Nov. 30, 2017USD ($)Target	Dec. 31, 2015USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2015USD ($)
Research Collaboration And License Agreements [Line Items]
Changes in deferred revenue due to billings			$ (7,883,755)	$ (5,006,582)
Revenue recognized on research collaboration and license agreements			10,900,000
Unsatisfied performance obligations expected to be recognized as revenue			54,200,000
Pfizer, Inc.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received			28,000,000
Changes in deferred revenue due to billings			3,000,000
Pfizer, Inc. | Option Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised			37,500,000
Pfizer, Inc. | Development Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised			225,000,000
Pfizer, Inc. | Sales-based Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised			$ 550,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received	$ 34,500,000	$ 11,000,000
Number of designated targets | Target	10
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised	$ 27,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised	44,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised	52,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised	$ 60,000,000
Merck Sharp & Dohme Corp.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received					$ 7,000,000
Agreement expiration period					2018-04

Research Collaboration and Li_4

Research Collaboration and License Agreements - Summary of Contract Liabilities (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Revenue From Contract With Customer [Abstract]
Contract liabilities	$ 54,215,006	$ 62,098,761
Amounts included in deferred revenue in previous periods	$ 10,354,342	$ 6,600,000

Research Collaboration and Li_5

Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details) $ in Millions	Sep. 30, 2018USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 54.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 3.4
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 13.5
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 13.5
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 13.5
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 8.6
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 1.7
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Research Collaboration and Li_6

Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1) $ in Millions	Sep. 30, 2018USD ($)
Revenue From Contract With Customer [Abstract]
Revenue, remaining performance obligation	$ 54.2

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Company's Available for Sale Securities (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 83,650,088
Gross Unrealized Losses	(47,223)
Fair Value	83,602,865
Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Effective Maturity		2,018
Amortized Cost	82,650,526	$ 8,268,732
Gross Unrealized Losses	(46,931)	(9,751)
Fair Value	$ 82,603,595	$ 8,258,982
Corporate Bonds | Minimum [Member]
Schedule Of Available For Sale Securities [Line Items]
Effective Maturity	2,018
Corporate Bonds | Maximum
Schedule Of Available For Sale Securities [Line Items]
Effective Maturity	2,019
Government Securities
Schedule Of Available For Sale Securities [Line Items]
Effective Maturity	2,018
Amortized Cost	$ 999,562
Gross Unrealized Losses	(292)
Fair Value	$ 999,270

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Assets:
Fair value measurements of assets	$ 83,602,865
Corporate Bonds | Fair Value, Measurements, Recurring
Assets:
Fair value measurements of assets	82,603,595	$ 8,258,982
Corporate Bonds | Fair Value, Measurements, Recurring | Level 2
Assets:
Fair value measurements of assets	82,603,595	8,258,982
Government Securities | Fair Value, Measurements, Recurring
Assets:
Fair value measurements of assets	999,270
Government Securities | Fair Value, Measurements, Recurring | Level 2
Assets:
Fair value measurements of assets	$ 999,270
Preferred Unit Warrant Liability | Fair Value, Measurements, Recurring
Liabilities:
Fair value measurements of liabilities		50,888
Preferred Unit Warrant Liability | Fair Value, Measurements, Recurring | Level 3
Liabilities:
Fair value measurements of liabilities		$ 50,888

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Changes In Level 3 Instruments Measured On Recurring Basis (Details) - Fair Value, Measurements, Recurring - Level 3 - Preferred Unit Warrant Liability - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 50,888	$ 56,759
Change in fair value	193,779	(4,338)
Exercise of warrant	(244,667)	0
Balance at end of period	$ 0	$ 52,421

Property, Equipment and Lease_3

Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Property, equipment and leasehold improvements, gross	$ 4,857,825	$ 2,330,501
Less: accumulated depreciation	(1,510,583)	(1,031,620)
Property, equipment and leasehold improvements, net	3,347,242	1,298,881
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property, equipment and leasehold improvements, gross	3,579,854	1,952,685
Office Equipment
Property Plant And Equipment [Line Items]
Property, equipment and leasehold improvements, gross	547,328	305,522
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, equipment and leasehold improvements, gross	$ 730,643	$ 72,294

Property, Equipment and Lease_4

Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation expense	$ 191,547	$ 92,147	$ 483,052	$ 246,367

Accrued Expenses - Components o

Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Employee expenses	$ 1,784,061	$ 1,047,022
Research and development expenses	1,912,377	1,982,525
Professional fees and other	1,154,708	516,389
Accrued expenses	$ 4,851,146	$ 3,545,936

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details)	Jan. 01, 2015USD ($)shares	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Jan. 31, 2014USD ($)Tranche	Aug. 31, 2013USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Debt instrument, outstanding amount		$ 2,214,309				$ 2,214,309		$ 2,214,309
Fair value of warrant						0	$ (1,546)	193,779	$ (4,338)
Total unamortized debt discount on Loan		10,299				10,299		10,299		$ 19,569
Amortization of debt discount								9,269	9,269
Discount on long-term debt		$ 10,299				10,299		10,299
Interest expense						$ 12,264	$ 12,219	$ 32,804	$ 38,905
2014 Assistance Agreement | State of Connecticut
Debt Instrument [Line Items]
Number of tranches for borrowing | Tranche				3
Debt instrument maturity month and year				2024-01
Debt instrument face amount				$ 2,500,000
Percentage of liquidated damages				7.50%
2018 Assistance Agreement | State of Connecticut
Debt Instrument [Line Items]
Debt instrument, interest rate per annum		3.25%				3.25%		3.25%
Debt instrument maturity month and year		2028-06
Debt instrument face amount		$ 2,000,000				$ 2,000,000		$ 2,000,000
Percentage of liquidated damages		7.50%
Percentage of maximum funding on total project costs			50.00%
Debt instrument interest payments term		60 months
Debt instrument amortization period after interest payments period		120 months
2018 Assistance Agreement | State of Connecticut | Maximum
Debt Instrument [Line Items]
Debt instrument face amount			$ 2,000,000
Forgiveness of funding on achieving certain employment conditions			$ 1,000,000
Series A Preferred Stock
Debt Instrument [Line Items]
Warrant to purchase of stock | shares					110,116
Warrant purchase price per share | $ / shares					$ 0.6811
Term of warrant from the date of issuance					7 years
Series A Redeemable Convertible Preferred Units
Debt Instrument [Line Items]
Warrant to purchase of stock | shares	110,116
Series A Preferred Unit Warrant
Debt Instrument [Line Items]
Fair value of warrant	$ 61,796
Loan Agreement | Connecticut Innovations, Inc. | Secured Debt
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity					$ 750,000
Debt instrument, frequency of periodic payment								monthly
Debt instrument, interest rate per annum					7.50%
Debt instrument, interest only payment period upon first draw of funds					10 months
Debt instrument, date of first required payment					Jun. 1, 2015
Debt instrument, maturity date					Jul. 31, 2019
Debt instrument, outstanding amount		$ 214,309				$ 214,309		$ 214,309		$ 343,500
Loan Agreement | Connecticut Innovations, Inc. | Secured Debt | Leasehold Improvements
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity					$ 100,000

Long-Term Debt - Schedule of As

Long-Term Debt - Schedule of Assumptions Used in Determining Fair Value of Warrant (Details) - Series A Preferred Unit Warrant	12 Months Ended
	Dec. 31, 2017$ / shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected term (years)	2 years 8 months 1 day
Fair value of underlying Series A redeemable convertible preferred units	$ 0.98
Expected Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assumption	1
Risk Free Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assumption	0.0191
Expected Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assumption	0

Long-Term Debt - Schedule of An

Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)	Sep. 30, 2018USD ($)
Long Term Debt By Maturity [Abstract]
2,018	$ 29,706
2,019	184,603
Beyond 5 years	2,000,000
Total	$ 2,214,309

Incentive Equity Plans - Additi

Incentive Equity Plans - Additional Information (Details) - USD ($)	1 Months Ended		9 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Incentive plan termination period	2018-09
Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incentive units authorized for issuance		6,199,477
Available for issuance of common stock	1,277,181		1,277,181
Incentive units granted	186,150		1,715,368
Weighted average fair value of incentive units granted			$ 4.54
Restricted shares granted	1,257,826
Stock options granted	1,744,650
Weighted average fair value of stock options granted			$ 9.87
Incentive Plan | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	1,995,660
Compensation expense	$ 3,627,507
Share options vested	357,658		357,658
Incentive Plan | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares and stock options vested and expected to vest	1,134,055		1,134,055
Incentive Plan | Employees And Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Compensation expense			$ 5,195,802
Compensation expense not yet recognized	$ 18,900,000		$ 18,900,000
Compensation expense not yet recognized, period of recognition			3 years
Incentive Plan | Consultants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted	11,097
Stock options granted	251,010
Compensation expense			$ 993,209
Compensation expense not yet recognized	$ 2,260,078		$ 2,260,078
Compensation expense not yet recognized, period of recognition			2 years
2018 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance of common stock	4,067,007		4,067,007
Annual increase in reserved shares of common stock	4,989,593
Annual increase in reserved shares as percentage of outstanding common stock	4.00%
2018 Stock Incentive Plan | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			2,181,810
Weighted average fair value of stock options granted			$ 10.13
Share options vested	357,658		357,658
Shares and stock options vested and expected to vest	1,949,915		1,949,915
Minimum [Member] | Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incentive units vesting period		1 year
Maximum | Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incentive units vesting period		4 years

Incentive Equity Plans - Schedu

Incentive Equity Plans - Schedule of Assumptions Used to Determine Fair Value of Incentive Common Units Granted and Stock Options Granted (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Incentive Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, Minimum	66.00%	75.00%
Expected volatility, Maximum	71.00%	78.00%
Risk free interest rate, Minimum	2.50%	1.10%
Risk free interest rate, Maximum	2.90%	2.10%
Expected dividend yield	0.00%	0.00%
Fair value of underlying common units		$ 0.72
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate, Minimum	2.90%
Risk free interest rate, Maximum	3.00%
Expected dividend yield	0.00%
Fair value of underlying common units	$ 16
Expected volatility	68.00%
Minimum [Member] | Incentive Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	5 years 7 months 6 days	1 year 6 months
Fair value of underlying common units	$ 1.08
Minimum [Member] | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	5 years
Maximum | Incentive Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	6 years 1 month 6 days	6 years 1 month 6 days
Fair value of underlying common units	$ 8.48
Maximum | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)	10 years

Incentive Equity Plans - Summar

Incentive Equity Plans - Summary of Incentive Unit Activity (Details) - Incentive Plan - Employees, Directors and Consultants	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units,Outstanding beginning balance | shares	3,669,963
Restricted shares granted | shares	1,715,368
Units,Forfeited | shares	(34,982)
Units,Cancelled | shares	(5,350,349)
Weighted Average Fair Value,Outstanding beginning balance | $ / shares	$ 0.45
Weighted average fair value of incentive units granted | $ / shares	4.54
Weighted Average Fair Value,Forfeited | $ / shares	4.85
Weighted Average Fair Value,Cancelled | $ / shares	$ 1.86

Incentive Equity Plans - Summ_2

Incentive Equity Plans - Summary of Restricted Stock Grant Activity (Details) - Incentive Plan - Restricted Stock	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units,Outstanding beginning balance | shares	0
Shares, Granted | shares	1,268,923
Units,Outstanding ending balance | shares	1,268,923
Weighted Average Fair Value,Outstanding beginning balance | $ / shares	$ 0
Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares	16
Weighted Average Fair Value,Outstanding ending balance | $ / shares	$ 16

Incentive Equity Plans - Summ_3

Incentive Equity Plans - Summary of Stock Option Activity (Details) - 2018 Plan - Stock Options	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Outstanding, Beginning Balance | shares	0
Options, Granted | shares	2,181,810
Options, Outstanding, Ending Balance | shares	2,181,810
Options, Exercisable, Ending Balance | shares	357,658
Weighted Average Fair Value, Outstanding, Beginning Balance | $ / shares	$ 0
Weighted Average Fair Value, Granted | $ / shares	10.13
Weighted Average Fair Value, Outstanding, Ending Balance | $ / shares	10.13
Weighted Average Fair Value, Exercisable, Ending Balance | $ / shares	$ 9.62

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Effective tax rate, percentage	0.00%	0.00%
Federal statutory rate, percentage	21.00%	34.00%
Effect of valuation allowance recorded against net deferred tax assets, percentage	0.00%
State income tax provision	$ 0	$ 0

Net Loss Per Common Share_Uni_2

Net Loss Per Common Share/Unit - Basic and Diluted Loss per Common Share/Unit (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Net loss	$ (13,387,672)	$ (6,397,272)	$ (25,392,600)	$ (19,321,180)
Change in fair value of redeemable convertible preferred stock/units	(112,050,609)	0	(198,366,756)	0
Net loss attributable to common shares/units—basic and diluted	$ (125,438,281)	$ (6,397,272)	$ (223,759,356)	$ (19,321,180)
Weighted average number of common shares/units outstanding, basic and diluted	2,010,807	1,897,544	1,935,299	1,897,544
Net loss per common stock/unit	$ (62.38)	$ (3.37)	$ (115.62)	$ (10.18)

Net Loss Per Common Share_Uni_3

Net Loss Per Common Share/Unit - Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	23,114,780	18,420,604
Redeemable Convertible Preferred Stock/Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	19,664,047	14,597,268
Incentive Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	0	3,789,455
Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	1,268,923
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	2,181,810
Preferred Unit Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common Share/Unit Equivalents Excluded from the Calculations of Diluted Loss Per Common Share/Unit	0	33,881

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Yale University
Related Party Transaction [Line Items]
Reimbursable patent costs	$ 107,289	$ 102,063
Consulting Agreement | Dr. Craig Crews
Related Party Transaction [Line Items]
Payment for consulting service	113,611	112,500
Monthly consulting service fee	$ 20,833
Consulting agreement term	3 years
Options, Granted	235,150
Exercise price of stock options	$ 16
Vesting period	3 years
Corporate Sponsored Research Agreement (SRA) | Yale University
Related Party Transaction [Line Items]
Quarterly research payments	$ 101,161
Total research payments	$ 601,161	$ 303,482
Related party agreement, description	In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, under the direction of Professor Crews, which was amended in April 2018. The SRA requires quarterly payments of $101,161 through April 2018, in exchange for performing the research on the agreed upon program and related research reports. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement.
Amended Corporate Sponsored Research Agreement | Yale University
Related Party Transaction [Line Items]
Quarterly research payments	$ 250,000